Navigation Links
Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.

Legacy of Regulatory Submissions Leadership Strengthened with Clinical

Trials Services and Standards-Based Data Management

WHIPPANY, N.J. and ATLANTA, Sept. 6 /PRNewswire/ -- Image Solutions, Inc. (ISI) announced today it agreed to terms to acquire Zurich Biostatistics, Inc. (ZBI). With the Life Sciences industry moving to standards-based regulatory submissions, the acquisition further strengthens ISI's Clinical Data Interchange Standards Consortium (CDISC) capabilities, the FDA-supported standard for clinical trials data and metadata.

"The FDA's embrace of CDISC standards presents pharma and biotech companies with a once-in-a-decade opportunity to streamline processes and harmonize operations with submissions," said Jinsoo Kim, ISI president and chief executive officer. "Our portfolio of clinical trials services gains instant experience and credential with the acquisition of ZBI."

ZBI and its president, Michael Palmer, pioneered the development and implementation of CDISC-based regulatory submissions. Palmer has co-authored and contributed to CDISC standards since 2000. He will continue at ISI as vice president of biometrics, overseeing the company's CDISC products and services.

"Over the next year, the FDA will rapidly move towards data standardization as a way to expedite innovation and bring new drugs to market faster and more effectively, an issue the industry is finding much more difficult then it was five years ago," said Palmer. "The health and well-being of millions of people is at stake -- the streamlining of drug development has never been more important."

ISI's acquisition of ZBI also bolsters the company's new biometrics' service line. Securing FDA approval on new drug submissions frequently hinges on the analyses of biometrics data. With clinical trials costing drug sponsors hundreds of millions of dollars, failed submissions can be detrimental. By adding highly qualified and experienced statisticians and programmers, ISI is able to help clients create statistical plans, conduct analyses and assist in the preparation of reports to avoid these pitfalls. Companies are also able to achieve more effective collaboration between statisticians and medical writers, speeding time to final CSR.

ZBI's core capabilities in biometrics analysis support ISI's commitment to complete, holistic regulatory submissions. Existing clients of both ISI and ZBI now have instant access to this approach and capability.

ISI is a pioneer in modernizing the regulatory submission process. The company enabled the first-ever electronic new drug application to the FDA and is at the forefront of the industry's move to adopting the electronic Common Technical Document (eCTD), the new drug application standard that will be required by the FDA at the end of 2007.

About Image Solutions, Inc.

Founded in 1992, Image Solutions, Inc. (ISI) is a proven market leader in providing submissions solutions, process services and consulting to Life Sciences companies as a way to improve clinical and regulatory processes that bring new medicines to market. ISI was among the first professional services firm to deliver electronic submissions to the industry and since has delivered more than 1,000 electronic submissions and 400 eCTD submissions. ISI serves the top 50 pharmaceutical and biotech organizations as well as the top companies in other regulated industries.

ISI is a privately held company with headquarters in Whippany, New Jersey and operations throughout the U.S., Europe and Asia. ISI also remains committed to giving back to society and sharing its success with others by donating 10 percent of annual net profits to over 20 recognized charitable organizations. For more information, visit the company Web site at

Press Contacts:

Lisa Meyer Kurt Rossler

Director, Global Marketing M Booth & Associates

973-560-0808 x. 217 212 481-7000

SOURCE Image Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Image of myosin-actin interaction revealed in cover story of Molecular Cell
2. Key heart and Alzheimers disease protein imaged for first time in native state
3. New MRI technique quickly builds 3-D images of knees
4. Everything in its place: Researchers identify brain cells used to categorize images
5. With record resolution and sensitivity, tool images how life organizes in a cell membrane
6. Researchers image molecular motor structural changes
7. Detailed 3-D image catches a key regulator of neural stem cell differentiation in action
8. CSIRO imagery shows Outer Great Barrier Reef at risk from river plumes
9. Novel computed imaging technique uses blurry images to enhance view
10. Ultrasound upgrade produces images that work like 3-D movies
11. Researchers wake up viruses inside tumors to image and then destroy cancers
Post Your Comments:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology: